Evidence map›Paper›PMID 41647352›Full record

ReviewESMO real world data and digital oncology2025

Characterisation of oncology EHR-derived real-world data in the UK, Germany, and Japan.

B Adamson, E Horne, C Xu, A Samani, C Buhl, P Mpofu, H Pittell, Q Zhang, D Ng, K Seidl-Rathkopf and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

B AdamsonFlatiron Health, New York, USA.
E HorneFlatiron Health UK, London, UK.
C XuFlatiron Health, New York, USA.
A SamaniFlatiron Health UK, London, UK.
C BuhlFlatiron Health Germany, Berlin, Germany.
P MpofuFlatiron Health, New York, USA.
H PittellFlatiron Health, New York, USA.
Q ZhangFlatiron Health, New York, USA.
D NgFlatiron Health K.K., Tokyo, Japan.
K Seidl-RathkopfFlatiron Health Germany, Berlin, Germany.
N SchinwaldFlatiron Health Germany, Berlin, Germany.
E TajimaFlatiron Health K.K., Tokyo, Japan.
A SujenthiranFlatiron Health UK, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncology real-world data (RWD) from electronic health records (EHRs) can generate real-world evidence crucial for clinical and policy decisions. However, challenges in accessing and harmonising data across countries limit its global applicability. Flatiron Health has developed oncology EHR-derived RWD datasets in the UK, Germany, and Japan, integrating these with its United States database to support multinational studies. This paper outlines the methods, aligned with the ISPOR EHR-derived data SUITABILITY checklist, to ensure the trustworthiness, reliability, and relevance of these datasets.

Indexed as

biomarkerselectronic health recordsGermanyJapanoncologyUK

Identifiers

PMID41647352
PMCPMC12836611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.